AL only | AL + 0.25 mg/kg PQ | AL + 0.40 mg/kg PQ | |
---|---|---|---|
Asymptomatic parasite carriers (Study Phase A) | |||
Female (%) | 51.6 | 52.0 | 53.4 |
Age (years) | 7.5 (4 – 10) | 8 (5 – 10) | 8 (4 – 10) |
Haemoglobin (g/dL) at enrolmenta | 10.8 (10.2 – 11.4) | 11.3 (10.7 – 11.9) | 11.7 (11.2 – 12.2) |
Asexual parasite levels at enrolment (parasites/μL; Microscopy) | 2,972.5 (1,147 – 6,865) | 2,503 (939 – 5,798) | 3,339 (874 – 7,358) |
Gametocyte prevalence (%) at enrolment (Microscopy) | 17.7 | 32.0 | 20.5 |
Gametocyte prevalence (%) at enrolment (QT-NASBA) | 96.4 | 92.9 | 85.5 |
Asymptomatic gametocyte carriers (Study Phase B) | |||
Female (%) | 43.1 | 46.0 | 42.9 |
Age (years) | 8 (5 – 11) | 7 (6 – 11) | 8 (6 – 11) |
Haemoglobin (g/dL) at enrolmenta | 11.4 (11.1 – 11.8) | 11.7 (11.4 – 12.1) | 11.5 (11.1 – 11.9) |
Asexual parasite levels at enrolment (parasites/μL; Microscopy) | 488 (226 – 1,670) | 957 (248 – 3,004) | 908.5 (198 – 2,297) |
Gametocyte prevalence (%) at screening (Microscopy) | 100 | 100 | 100 |
Gametocyte prevalence (%) at enrolment (Microscopy) | 69.4 | 55.3 | 83.3 |
Gametocyte prevalence (%) at enrolment (QT-NASBA) | 95.9 | 93.7 | 100.0 |
Gametocyte levels at enrolment (parasites/μL)b | 17.3 (7.2 - 45.1) | 18.6 (7.8 - 75.3) | 16.6 (7.2 - 40.0) |